Novel targeted therapeutics for metastatic castration-resistant prostate cancer
ES Antonarakis, MA Carducci, MA Eisenberger - Cancer letters, 2010 - Elsevier
Virtually all patients that succumb to prostate cancer die of metastatic castration-resistant
disease. Although docetaxel is the standard of care for these patients and is associated with …
disease. Although docetaxel is the standard of care for these patients and is associated with …
[引用][C] Novel targeted therapeutics for metastatic castration-resistant prostate cancer
ES Antonarakis, MA Carducci, MA Eisenberger - Cancer Letters, 2010 - cir.nii.ac.jp
Novel targeted therapeutics for metastatic castration-resistant prostate cancer | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Novel targeted therapeutics for metastatic castration-resistant prostate cancer
ES Antonarakis, MA Carducci… - Cancer …, 2010 - pubmed.ncbi.nlm.nih.gov
Virtually all patients that succumb to prostate cancer die of metastatic castration-resistant
disease. Although docetaxel is the standard of care for these patients and is associated with …
disease. Although docetaxel is the standard of care for these patients and is associated with …
Novel targeted therapeutics for metastatic castration-resistant prostate cancer
ES Antonarakis, MA Carducci… - Cancer Letters, 2010 - pure.johnshopkins.edu
Virtually all patients that succumb to prostate cancer die of metastatic castration-resistant
disease. Although docetaxel is the standard of care for these patients and is associated with …
disease. Although docetaxel is the standard of care for these patients and is associated with …
Novel targeted therapeutics for metastatic castration-resistant prostate cancer.
ES Antonarakis, MA Carducci, MA Eisenberger - Cancer Letters, 2009 - europepmc.org
Virtually all patients that succumb to prostate cancer die of metastatic castration-resistant
disease. Although docetaxel is the standard of care for these patients and is associated with …
disease. Although docetaxel is the standard of care for these patients and is associated with …
Novel targeted therapeutics for metastatic castration-resistant prostate cancer
ES Antonarakis, MA Carducci, MA Eisenberger - Cancer Letters, 2010 - infona.pl
Virtually all patients that succumb to prostate cancer die of metastatic castration-resistant
disease. Although docetaxel is the standard of care for these patients and is associated with …
disease. Although docetaxel is the standard of care for these patients and is associated with …
Novel targeted therapeutics for metastatic castration-resistant prostate cancer
ES Antonarakis, MA Carducci, MA Eisenberger - Cancer Letters, 2010 - experts.umn.edu
Virtually all patients that succumb to prostate cancer die of metastatic castration-resistant
disease. Although docetaxel is the standard of care for these patients and is associated with …
disease. Although docetaxel is the standard of care for these patients and is associated with …
[HTML][HTML] Novel targeted therapeutics for metastatic castration-resistant prostate cancer
ES Antonarakis, MA Carducci, MA Eisenberger - Cancer letters, 2010 - ncbi.nlm.nih.gov
Virtually all patients that succumb to prostate cancer die of metastatic castration-resistant
disease. Although docetaxel is the standard of care for these patients and is associated with …
disease. Although docetaxel is the standard of care for these patients and is associated with …